Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome

The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low. The frequency of the risk factors that constitute the metabolic syndrome and are associ...

Full description

Saved in:
Bibliographic Details
Institution:Universidad EIA
Main Authors: Lopez-Jaramillo, Patricio, Barbosa, Eduardo, Molina, Dora I., Sánchez, Ramiro, Diaz, Margarita, Camacho López, Paul Anthony, Lanas, Fernando, Pasquel, Miguel, Accini, Jose Luis, Ponte Negretti, Carlos I., Alcocer, Luis, Cobos, Leonardo, Wyss, Fernando, Sebba-Barroso, Weimar, Coca, Antonio, Zanchetti, Alberto
Format: Artículo de revista
Language:English
Published: 2019-06
Subjects:
Online Access:https://repositorio.udes.edu.co/handle/001/3097
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:null:001-3097
recordtype dspace
spelling Lopez-Jaramillo, Patricio
Barbosa, Eduardo
Molina, Dora I.
Sánchez, Ramiro
Diaz, Margarita
Camacho López, Paul Anthony
Lanas, Fernando
Pasquel, Miguel
Accini, Jose Luis
Ponte Negretti, Carlos I.
Alcocer, Luis
Cobos, Leonardo
Wyss, Fernando
Sebba-Barroso, Weimar
Coca, Antonio
Zanchetti, Alberto
2019-06-18T12:40:21Z
2019-06-18T12:40:21Z
2019-06
22 p. Electrónico
The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low. The frequency of the risk factors that constitute the metabolic syndrome and are associated with an increased risk of cardiovascular disease has not diminished since the publication of the previous consensus. This document discusses the socioeconomic, demographic, environmental and cultural characteristics of most associated Latin American countries and partially explains the lack of better results in improving clinical and public health actions that allow high morbidity and mortality rates caused by cardiovascular diseases and DM2 to be reduced through programs aligned with the so-called precision medicine, which should be predictive, preventive, personalized and participatory. The Consensus ratifies the diagnostic criteria expressed in the previous consensus to define hypertension and DM2 but, for the metabolic syndrome, and in the absence of evidence, the recommendation is to implement a cohort study that determines the abdominal perimeter value associated with hard outcomes, such as DM2 and CVD. Meanwhile, we recommend modifying the criterion to more than 94 cm in men and more than 84 cm in women according to WHO recommendations. We also recommend the carrying out of a study that identifies the situation of hypertension and DM2 in people of African ancestry who, in Latin America, exceed 75 million and whose epidemiology does not include solid studies. With respect to the proposed therapeutic targets, we recommended maintaining those defined in the previous consensus, but insisting that early pharmacological management of prediabetes with metformin should be introduced, as should the treatment of diabetic hypertensive patients with a combination therapy of two fixed-dose antihypertensive drugs and management with statins. To increase adherence, the use of different drugs combined in a single pill (polypill) is recommended. The simplification of the therapeutic regimen is accompanied by greater control of cardiovascular risk factors, both in primary and secondary prevention, and has been shown to be cost-effective. The consensus recommends the use of the currently available polypill combining an angiotensin-converting enzyme inhibitor, a statin and aspirin for secondary cardiovascular prevention and in patients with a high cardiovascular risk, such as hypertension patients with DM2.
application/pdf
10.1097/HJH.0000000000002072
0263-6352
1473-5598
https://repositorio.udes.edu.co/handle/001/3097
eng
Journal of Hypertension
Rights - Wolters Kluwer Health, Inc., 2019
info:eu-repo/semantics/openAccess
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
https://creativecommons.org/licenses/by-nc/4.0/
https://journals.lww.com/jhypertension/fulltext/2019/06000/Latin_American_Consensus_on_the_management_of.5.aspx
Hypertension
Metabolic syndrome
Type 2 diabetes mellitus
Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
Artículo de revista
http://purl.org/coar/resource_type/c_6501
Text
info:eu-repo/semantics/article
http://purl.org/redcol/resource_type/ART
info:eu-repo/semantics/publishedVersion
Publication
http://purl.org/coar/access_right/c_abf2
http://purl.org/coar/version/c_970fb48d4fbd8a85
institution Universidad EIA
collection d_repositorio.udes.edu.co-DSPACE
title Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
spellingShingle Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
Lopez-Jaramillo, Patricio
Barbosa, Eduardo
Molina, Dora I.
Sánchez, Ramiro
Diaz, Margarita
Camacho López, Paul Anthony
Lanas, Fernando
Pasquel, Miguel
Accini, Jose Luis
Ponte Negretti, Carlos I.
Alcocer, Luis
Cobos, Leonardo
Wyss, Fernando
Sebba-Barroso, Weimar
Coca, Antonio
Zanchetti, Alberto
Lopez-Jaramillo, Patricio
Barbosa, Eduardo
Molina, Dora I.
Sánchez, Ramiro
Diaz, Margarita
Camacho López, Paul Anthony
Lanas, Fernando
Pasquel, Miguel
Accini, Jose Luis
Ponte Negretti, Carlos I.
Alcocer, Luis
Cobos, Leonardo
Wyss, Fernando
Sebba-Barroso, Weimar
Coca, Antonio
Zanchetti, Alberto
Hypertension
Metabolic syndrome
Type 2 diabetes mellitus
title_short Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
title_full Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
title_fullStr Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
title_full_unstemmed Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
title_sort latin american consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome
author Lopez-Jaramillo, Patricio
Barbosa, Eduardo
Molina, Dora I.
Sánchez, Ramiro
Diaz, Margarita
Camacho López, Paul Anthony
Lanas, Fernando
Pasquel, Miguel
Accini, Jose Luis
Ponte Negretti, Carlos I.
Alcocer, Luis
Cobos, Leonardo
Wyss, Fernando
Sebba-Barroso, Weimar
Coca, Antonio
Zanchetti, Alberto
Lopez-Jaramillo, Patricio
Barbosa, Eduardo
Molina, Dora I.
Sánchez, Ramiro
Diaz, Margarita
Camacho López, Paul Anthony
Lanas, Fernando
Pasquel, Miguel
Accini, Jose Luis
Ponte Negretti, Carlos I.
Alcocer, Luis
Cobos, Leonardo
Wyss, Fernando
Sebba-Barroso, Weimar
Coca, Antonio
Zanchetti, Alberto
author_facet Lopez-Jaramillo, Patricio
Barbosa, Eduardo
Molina, Dora I.
Sánchez, Ramiro
Diaz, Margarita
Camacho López, Paul Anthony
Lanas, Fernando
Pasquel, Miguel
Accini, Jose Luis
Ponte Negretti, Carlos I.
Alcocer, Luis
Cobos, Leonardo
Wyss, Fernando
Sebba-Barroso, Weimar
Coca, Antonio
Zanchetti, Alberto
Lopez-Jaramillo, Patricio
Barbosa, Eduardo
Molina, Dora I.
Sánchez, Ramiro
Diaz, Margarita
Camacho López, Paul Anthony
Lanas, Fernando
Pasquel, Miguel
Accini, Jose Luis
Ponte Negretti, Carlos I.
Alcocer, Luis
Cobos, Leonardo
Wyss, Fernando
Sebba-Barroso, Weimar
Coca, Antonio
Zanchetti, Alberto
building Repositorio digital
topic Hypertension
Metabolic syndrome
Type 2 diabetes mellitus
topic_facet Hypertension
Metabolic syndrome
Type 2 diabetes mellitus
publishDate 2019-06
language English
format Artículo de revista
description The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low. The frequency of the risk factors that constitute the metabolic syndrome and are associated with an increased risk of cardiovascular disease has not diminished since the publication of the previous consensus. This document discusses the socioeconomic, demographic, environmental and cultural characteristics of most associated Latin American countries and partially explains the lack of better results in improving clinical and public health actions that allow high morbidity and mortality rates caused by cardiovascular diseases and DM2 to be reduced through programs aligned with the so-called precision medicine, which should be predictive, preventive, personalized and participatory. The Consensus ratifies the diagnostic criteria expressed in the previous consensus to define hypertension and DM2 but, for the metabolic syndrome, and in the absence of evidence, the recommendation is to implement a cohort study that determines the abdominal perimeter value associated with hard outcomes, such as DM2 and CVD. Meanwhile, we recommend modifying the criterion to more than 94 cm in men and more than 84 cm in women according to WHO recommendations. We also recommend the carrying out of a study that identifies the situation of hypertension and DM2 in people of African ancestry who, in Latin America, exceed 75 million and whose epidemiology does not include solid studies. With respect to the proposed therapeutic targets, we recommended maintaining those defined in the previous consensus, but insisting that early pharmacological management of prediabetes with metformin should be introduced, as should the treatment of diabetic hypertensive patients with a combination therapy of two fixed-dose antihypertensive drugs and management with statins. To increase adherence, the use of different drugs combined in a single pill (polypill) is recommended. The simplification of the therapeutic regimen is accompanied by greater control of cardiovascular risk factors, both in primary and secondary prevention, and has been shown to be cost-effective. The consensus recommends the use of the currently available polypill combining an angiotensin-converting enzyme inhibitor, a statin and aspirin for secondary cardiovascular prevention and in patients with a high cardiovascular risk, such as hypertension patients with DM2.
issn 0263-6352
url https://repositorio.udes.edu.co/handle/001/3097
url_str_mv https://repositorio.udes.edu.co/handle/001/3097
_version_ 1789502220174098432
score 11.2563715